Ramesk K Ramanathan, MD &ndash; Research Output

2019

A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer

Ramanathan, R. K., Thomas, G. W., Khorana, A. A., Shah, S., Zhou, C., Wong, S., Cole, G., James, D. & Gabrail, N. Y., Jan 1 2019, In : Oncology (Switzerland).

Research output: Contribution to journal › Article

Open Access

gemcitabine

Factor VIIa

Pancreatic Neoplasms

Disease-Free Survival

Survival

Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer (British Journal of Cancer, (2019), 120, 2, (183-189), 10.1038/s41416-018-0343-z)

Gorbunova, V., Beck, J. T., Hofheinz, R. D., Garcia-Alfonso, P., Nechaeva, M., Gracian, A. C., Mangel, L., Fernandez, E. E., Deming, D. A., Ramanathan, R. K., Torres, A. H., Sullivan, D., Luo, Y. & Berlin, J. D., Jan 1 2019, In : British journal of cancer.

Research output: Contribution to journal › Comment/debate

Open Access

Colorectal Neoplasms

Placebos

Neoplasms

veliparib

6 Citations (Scopus)

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial

Shroff, R. T., Javle, M. M., Xiao, L., Kaseb, A. O., Varadhachary, G. R., Wolff, R. A., Raghav, K. P. S., Iwasaki, M., Masci, P., Ramanathan, R. K., Ahn, D., Bekaii-Saab, T. & Borad, M. J., Jan 1 2019, In : JAMA Oncology.

Research output: Contribution to journal › Article

gemcitabine

Biliary Tract Neoplasms

Nanoparticles

Cisplatin

Clinical Trials

13 Citations (Scopus)

Hepatocytes direct the formation of a pro-metastatic niche in the liver

Lee, J. W., Stone, M. L., Porrett, P. M., Thomas, S. K., Komar, C. A., Li, J. H., Delman, D., Graham, K., Gladney, W. L., Hua, X., Black, T. A., Chien, A. L., Majmundar, K. S., Thompson, J. C., Yee, S. S., O’Hara, M. H., Aggarwal, C., Xin, D., Shaked, A., Gao, M. & 9 others, Liu, D., Borad, M. J., Ramanathan, R. K., Carpenter, E. L., Ji, A., de Beer, M. C., de Beer, F. C., Webb, N. R. & Beatty, G. L., Mar 14 2019, In : Nature. 567, 7747, p. 249-252 4 p.

Research output: Contribution to journal › Letter

Hepatocytes

Liver

STAT3 Transcription Factor

Neoplasm Metastasis

Circulating Neoplastic Cells

5 Citations (Scopus)

Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313

Ramanathan, R. K., McDonough, S. L., Philip, P. A., Hingorani, S. R., Lacy, J., Kortmansky, J. S., Thumar, J., Chiorean, E. G., Shields, A. F., Behl, D., Mehan, P. T., Gaur, R., Seery, T., Guthrie, K. A. & Hochster, H. S., May 1 2019, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 37, 13, p. 1062-1069 8 p.

Research output: Contribution to journal › Article

Hyaluronoglucosaminidase

Adenocarcinoma

Hyaluronic Acid

Survival

irinotecan

2018

3 Citations (Scopus)

A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours

Berlin, J., Ramanathan, R. K., Strickler, J. H., Subramaniam, D. S., Marshall, J., Kang, Y. K., Hetman, R., Dudley, M. W., Zeng, J., Nickner, C., Xiong, H., Komarnitsky, P., Shepherd, S. P., Hurwitz, H. & Lenz, H. J., Mar 12 2018, (Accepted/In press) In : British Journal of Cancer. p. 1-9 9 p.

Research output: Contribution to journal › Article

irinotecan

Neoplasms

Fluorouracil

Maximum Tolerated Dose

Leucovorin

1 Citation (Scopus)

A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer

Gorbunova, V., Beck, J. T., Hofheinz, R. D., Garcia-Alfonso, P., Nechaeva, M., Cubillo Gracian, A., Mangel, L., Elez Fernandez, E., Deming, D. A., Ramanathan, R. K., Torres, A. H., Sullivan, D., Luo, Y. & Berlin, J. D., Jan 1 2018, (Accepted/In press) In : British Journal of Cancer.

Research output: Contribution to journal › Article

Colorectal Neoplasms

Placebos

Neutropenia

Disease-Free Survival

veliparib

2 Citations (Scopus)

Emerging therapies and future directions in targeting the tumor stroma and immune system in the treatment of pancreatic adenocarcinoma

Ahn, D., Ramanathan, R. K. & Bekaii-Saab, T., Jun 11 2018, In : Cancers. 10, 6, 193.

Research output: Contribution to journal › Review article

Immune System

Adenocarcinoma

Neoplasms

Therapeutics

Aptitude

3 Citations (Scopus)

First-in-human phase I, dose-escalation and -expansion study of telisotuzumab vedotin, an antibody–drug conjugate targeting c-Met, in patients with advanced solid tumors

Strickler, J. H., Weekes, C. D., Nemunaitis, J., Ramanathan, R. K., Heist, R. S., Morgensztern, D., Angevin, E., Bauer, T. M., Yue, H., Motwani, M., Parikh, A., Reilly, E. B., Afar, D., Naumovski, L. & Kelly, K., Nov 20 2018, In : Journal of Clinical Oncology. 36, 33, p. 3298-3306 9 p.

Research output: Contribution to journal › Article

Non-Small Cell Lung Carcinoma

Neoplasms

Maximum Tolerated Dose

Safety

Fatigue

17 Citations (Scopus)

Metastatic pancreatic cancer: ASCO clinical practice guideline update

Sohal, D. P. S., Kennedy, E. B., Khorana, A., Copur, M. S., Crane, C. H., Garrido-Laguna, I., Krishnamurthi, S., Moravek, C., O'Reilly, E. M., Philip, P. A., Ramanathan, R. K., Ruggiero, J. T., Shah, M. A., Urba, S., Uronis, H. E., Lau, M. W. & Laheru, D., Aug 20 2018, In : Journal of Clinical Oncology. 36, 24, p. 2545-2556 12 p.

Research output: Contribution to journal › Review article

irinotecan

Pancreatic Neoplasms

Practice Guidelines

gemcitabine

Fluorouracil

Novel immunotherapy strategies for hepatobiliary cancers

Deleon, T. T., Zhou, Y., Nagalo, B., Yokoda, R. T., Ahn, D., Ramanathan, R. K., Salomao, M. A., Aqel, B. A., Mahipal, A., Bekaii-Saab, T. & Borad, M. J., Sep 1 2018, In : Immunotherapy. 10, 12, p. 1077-1091 15 p.

Research output: Contribution to journal › Review article

Immunotherapy

Neoplasms

Oncolytic Virotherapy

Therapeutics

T-Cell Antigen Receptor

8 Citations (Scopus)

Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma

Deleon, T. T., Ahn, D., Bogenberger, J. M., Anastasiadis, P. Z., Arora, M., Ramanathan, R. K., Aqel, B. A., Vasmatzis, G., Truty, M., Oklu, R., Bekaii-Saab, T. & Borad, M. J., Mar 1 2018, In : Future Oncology. 14, 6, p. 553-566 14 p.

Research output: Contribution to journal › Review article

Biliary Tract Neoplasms

Hepatocellular Carcinoma

Neoplasms

Biomarkers

Therapeutics

14 Citations (Scopus)

Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours

Infante, J. R., Korn, R. L., Rosen, L. S., Lorusso, P., Dychter, S. S., Zhu, J., Maneval, D. C., Jiang, P., Shepard, H. M., Frost, G., Von Hoff, D. D., Borad, M. J. & Ramanathan, R. K., Jan 1 2018, In : British Journal of Cancer. 118, 2, p. 153-161 9 p.

Research output: Contribution to journal › Article

Hyaluronoglucosaminidase

Neoplasms

Hyaluronic Acid

Maximum Tolerated Dose

Myalgia

65 Citations (Scopus)

Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma

Javle, M., Lowery, M., Shroff, R. T., Weiss, K. H., Springfeld, C., Borad, M. J., Ramanathan, R. K., Goyal, L., Sadeghi, S., Macarulla, T., El-Khoueiry, A., Kelley, R. K., Borbath, I., Choo, S. P., Oh, D. Y., Philip, P. A., Chen, L. T., Reungwetwattana, T., Van Cutsem, E., Yeh, K. H. & 9 others, Ciombor, K., Finn, R. S., Patel, A., Sen, S., Porter, D., Isaacs, R., Zhu, A. X., Abou-Alfa, G. K. & Bekaii-Saab, T., Jan 20 2018, In : Journal of Clinical Oncology. 36, 3, p. 276-282 7 p.

Research output: Contribution to journal › Article

Receptor, Fibroblast Growth Factor, Type 2

Cholangiocarcinoma

Hyperphosphatemia

Stomatitis

gemcitabine

4 Citations (Scopus)

Phase I study of enavatuzumab, a first-in-class humanized monoclonal antibody targeting the TWEAK receptor, in patients with advanced solid tumors

Lam, E. T., Eckhardt, S. G., Messersmith, W., Jimeno, A., O'Bryant, C. L., Ramanathan, R. K., Weiss, G. J., Chadha, M., Oey, A., Ding, H. T., Culp, P. A., Keller, S. F., Zhao, V. Y., Tsao, L. C., Singhal, A., Holen, K. D. & Von Hoff, D., Jan 1 2018, In : Molecular Cancer Therapeutics. 17, 1, p. 215-221 7 p.

Research output: Contribution to journal › Article

Antibodies, Monoclonal, Humanized

Pharmacokinetics

Neoplasms

Liver

Enzymes

2017

3 Citations (Scopus)

¹⁸F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer

Korn, R. L., Von Hoff, D. D., Borad, M. J., Renschler, M. F., McGovern, D., Curtis Bay, R. & Ramanathan, R. K., Aug 3 2017, In : Cancer Imaging. 17, 1, 23.

Research output: Contribution to journal › Article

gemcitabine

Fluorodeoxyglucose F18

Pancreatic Neoplasms

Positron-Emission Tomography

Survival

A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients

Ramanathan, R. K., Weiss, G. J., Posner, R. G., Rajeshkumar, N. V., Jameson, G., Aziz, M., Hoering, A., Bolejack, V., Maitra, A., Fulk, M., Stites, E. C., Hlavacek, W. S., Gatalica, Z., Xiu, J., Hidalgo, M., Von Hoff, D. D. & Barrett, M., Dec 1 2017, In : Journal of Gastrointestinal Oncology. 8, 6, p. 925-935 11 p.

Research output: Contribution to journal › Article

Pancreatic Neoplasms

Immunohistochemistry

Neoplasms

Biopsy

irinotecan

9 Citations (Scopus)

Clinical study of genomic drivers in pancreatic ductal adenocarcinoma

Barrett, M., Deiotte, R., Lenkiewicz, E., Malasi, S., Holley, T., Evers, L., Posner, R. G., Jones, T., Han, H., Sausen, M., Velculescu, V. E., Drebin, J., O'Dwyer, P., Jameson, G., Ramanathan, R. K. & Von Hoff, D. D., Aug 8 2017, In : British Journal of Cancer. 117, 4, p. 572-582 11 p.

Research output: Contribution to journal › Article

Adenocarcinoma

Genome

Neoplasms

DNA Repair-Deficiency Disorders

Clinical Trials

34 Citations (Scopus)

Correlation between ferumoxytol uptake in tumor lesions by MRI and response to nanoliposomal irinotecan in patients with advanced solid tumors: A pilot study

Ramanathan, R. K., Korn, R. L., Raghunand, N., Sachdev, J. C., Newbold, R. G., Jameson, G., Fetterly, G. J., Prey, J., Klinz, S. G., Kim, J., Cain, J., Hendriks, B. S., Drummond, D. C., Bayever, E. & Fitzgerald, J. B., Jul 15 2017, In : Clinical Cancer Research. 23, 14, p. 3638-3648 11 p.

Research output: Contribution to journal › Article

irinotecan

Ferrosoferric Oxide

Neoplasms

Development of new pharmaceutical therapies for pancreatic adenocarcinoma

Ramanathan, R. K., Nov 1 2017, In : Clinical Advances in Hematology and Oncology. 15, 11, p. 7-10 4 p.

Research output: Contribution to journal › Article

Adenocarcinoma

Pharmaceutical Preparations

Therapeutics

21 Citations (Scopus)

Immunotherapy in pancreatic cancer treatment: A new frontier

Thind, K., Padrnos, L. J., Ramanathan, R. K. & Borad, M. J., Jan 1 2017, In : Therapeutic Advances in Gastroenterology. 10, 1, p. 168-194 27 p.

Research output: Contribution to journal › Review article

Pancreatic Neoplasms

Immunotherapy

Tumor Microenvironment

Therapeutics

Immune Tolerance

106 Citations (Scopus)

Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers

de Bono, J., Ramanathan, R. K., Mina, L., Chugh, R., Glaspy, J., Rafii, S., Kaye, S., Sachdev, J., Heymach, J., Smith, D. C., Henshaw, J. W., Herriott, A., Patterson, M., Curtin, N. J., Byers, L. A. & Wainberg, Z. A., 2017, In : Cancer Discovery. 7, 6, p. 620-629 10 p.

Research output: Contribution to journal › Article

Mutation

Neoplasms

Small Cell Lung Carcinoma

Antineoplastic Agents

Ovarian Neoplasms

4 Citations (Scopus)

Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors

Weiss, G. J., Jameson, G., von Hoff, D. D., Valsasina, B., Davite, C., Di Giulio, C., Fiorentini, F., Alzani, R., Carpinelli, P., Di Sanzo, A., Galvani, A., Isacchi, A. & Ramanathan, R. K., Jul 20 2017, (Accepted/In press) In : Investigational New Drugs. p. 1-11 11 p.

Research output: Contribution to journal › Article

Maximum Tolerated Dose

Neoplasms

Oral Administration

Safety

Therapeutics

47 Citations (Scopus)

Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors

Juric, D., Krop, I., Ramanathan, R. K., Wilson, T. R., Ware, J. A., Sanabria Bohorquez, S. M., Savage, H. M., Sampath, D., Salphati, L., Lin, R. S., Jin, H., Parmar, H., Hsu, J. Y., Von Hoff, D. D. & Baselga, J., Jul 1 2017, In : Cancer Discovery. 7, 7, p. 704-715 12 p.

Research output: Contribution to journal › Article

Phosphatidylinositol 3-Kinases

Neoplasms

Growth Inhibitors

Stomatitis

Mutation

13 Citations (Scopus)

Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis

Borazanci, E., Millis, S. Z., Kimbrough, J., Doll, N., von Hoff, D. & Ramanathan, R. K., 2017, In : Journal of Gastrointestinal Oncology. 8, 1, p. 164-172 9 p.

Research output: Contribution to journal › Article

Appendiceal Neoplasms

Fluorescence In Situ Hybridization

Immunohistochemistry

irinotecan

Goblet Cells

Recent advances in the treatment of pancreatic adenocarcinoma: Further observations

Ramanathan, R. K. & Bekaii-Saab, T., Nov 1 2017, In : Clinical Advances in Hematology and Oncology. 15, 11, 1 p.

Research output: Contribution to journal › Comment/debate

Adenocarcinoma

Recent advances in the treatment of pancreatic adenocarcinoma

Braiteh, F., Ramanathan, R. K. & Bekaii-Saab, T., Nov 1 2017, In : Clinical Advances in Hematology and Oncology. 15, 11, p. 1-2 2 p.

Research output: Contribution to journal › Article

gemcitabine

Pancreatic Neoplasms

Adenocarcinoma

irinotecan

oxaliplatin

9 Citations (Scopus)

Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis

Sonbol, M. B., Firwana, B., Wang, Z., Almader-Douglas, D., Borad, M. J., Makhoul, I., Ramanathan, R. K., Ahn, D. & Bekaii-Saab, T., Dec 1 2017, In : Cancer. 123, 23, p. 4680-4686 7 p.

Research output: Contribution to journal › Article

oxaliplatin

irinotecan

Meta-Analysis

Adenocarcinoma

Disease-Free Survival

1 Citation (Scopus)

Targeting the stroma in pancreatic cancer

Ahn, D. & Ramanathan, R. K., Dec 1 2017, In : Chinese Clinical Oncology. 6, 6, 65.

Research output: Contribution to journal › Review article

Pancreatic Neoplasms

Tumor Microenvironment

Therapeutic Uses

Immunosuppression

Neoplasms

10 Citations (Scopus)

Tumor reduction in primary andmetastatic pancreatic cancer lesions with nab-paclitaxel and gemcitabine: An exploratory analysis from a phase 3 study

Kunzmann, V., Ramanathan, R. K., Goldstein, D., Liu, H., Ferrara, S., Lu, B., Renschler, M. F. & Von Hoff, D. D., 2017, In : Pancreas. 46, 2, p. 203-208 6 p.

Research output: Contribution to journal › Article

gemcitabine

Pancreatic Neoplasms

Tumor Burden

Neoplasms

Adenocarcinoma

Virotherapies in pancreatic cancer

Ahn, D. & Ramanathan, R. K., Sep 27 2017, Current and Emerging Therapies in Pancreatic Cancer. Springer International Publishing, p. 309-322 14 p.

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Pancreatic Neoplasms

2016

1 Citation (Scopus)

A Case Report of Ischemic Stroke in a Patient with Metastatic Gastric Cancer Secondary to Treatment with the Vascular Endothelial Growth Factor Receptor-2 Inhibitor Ramucirumab

Christiansen, M. E., Ingall, T., Lew, E. C., Ramanathan, R. K. & Paripati, H., 2016, In : Case Reports in Oncology. 9, 2, p. 317-320 4 p.

Research output: Contribution to journal › Article

Vascular Endothelial Growth Factor Receptor-2

Stomach Neoplasms

Stroke

Thromboembolism

Brain Ischemia

34 Citations (Scopus)

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

Chiorean, E. G., Von Hoff, D. D., Reni, M., Arena, F. P., Infante, J. R., Bathini, V. G., Wood, T. E., Mainwaring, P. N., Muldoon, R. T., Clingan, P. R., Kunzmann, V., Ramanathan, R. K., Tabernero, J., Goldstein, D., McGovern, D., Lu, B. & Ko, A., Apr 1 2016, In : Annals of Oncology. 27, 4, p. 654-660 7 p., mdw006.

Research output: Contribution to journal › Article

gemcitabine

Pancreatic Neoplasms

Survival

130-nm albumin-bound paclitaxel

24 Citations (Scopus)

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: A cohort study

Kasi, P. M., Kotani, D., Cecchini, M., Shitara, K., Ohtsu, A., Ramanathan, R. K., Hochster, H. S., Grothey, A. F. & Yoshino, T., Jul 13 2016, In : BMC Cancer. 16, 1, 467.

Research output: Contribution to journal › Article

Neutropenia

Colorectal Neoplasms

Cohort Studies

Drug Therapy

Survival

10 Citations (Scopus)

Clinical Implementation of Integrated Genomic Profiling in Patients with Advanced Cancers

Borad, M. J., Egan, J. B., Condjella, R. M., Liang, W. S., Fonseca, R., Ritacca, N. R., McCullough, A. E., Barrett, M., Hunt, K. S., Champion, M. D., Patel, M. D., Young, S. W., Silva, A. C., Ho, T. H., Halfdanarson, T. R., Mc Williams, R. R., Lazaridis, K. N., Ramanathan, R. K., Baker, A., Aldrich, J. & 17 others, Kurdoglu, A., Izatt, T., Christoforides, A., Cherni, I., Nasser, S., Reiman, R., Cuyugan, L., McDonald, J., Adkins, J., Mastrian, S. D., Valdez, R., Jaroszewski, D. E., Von Hoff, D. D., Craig, D. W., Stewart, A. K., Carpten, J. D. & Bryce, A. H., 2016, In : Scientific Reports. 6, 1, 25.

Research output: Contribution to journal › Article

Neoplasms

Therapeutics

DNA Fingerprinting

Patient Preference

Pharmaceutical Preparations

17 Citations (Scopus)

Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)

Goldstein, D., Von Hoff, D. D., Moore, M., Greeno, E., Tortora, G., Ramanathan, R. K., Macarulla, T., Liu, H., Pilot, R., Ferrara, S. & Lu, B., Jan 1 2016, In : European Journal of Cancer. 52, p. 85-91 7 p.

Research output: Contribution to journal › Article

gemcitabine

Peripheral Nervous System Diseases

Pancreas

Adenocarcinoma

Survival

19 Citations (Scopus)

Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: Phase III MPACT trial

Scheithauer, W., Ramanathan, R. K., Moore, M., Macarulla, T., Goldstein, D., Hammel, P., Kunzmann, V., Liu, H., McGovern, D., Romano, A. & Von Hoff, D. D., Jun 1 2016, In : Journal of Gastrointestinal Oncology. 7, 3, p. 469-478 10 p.

Research output: Contribution to journal › Article

gemcitabine

Pancreatic Neoplasms

Neutropenia

Thrombocytopenia

Fatigue

53 Citations (Scopus)

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

Patnaik, A., Appleman, L. J., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Weiss, G. J., Sachdev, J. C., Chadha, M., Fulk, M., Ejadi, S., Mountz, J. M., Lotze, M. T., Toledo, F. G. S., Chu, E., Jeffers, M., Peña, C., Xia, C., Reif, S., Genvresse, I. & 1 others, Ramanathan, R. K., Oct 1 2016, In : Annals of oncology : official journal of the European Society for Medical Oncology. 27, 10, p. 1928-1940 13 p.

Research output: Contribution to journal › Article

Class I Phosphatidylinositol 3-Kinases

Non-Hodgkin's Lymphoma

Maximum Tolerated Dose

Neoplasms

Follicular Lymphoma

3 Citations (Scopus)

Hepatoid Carcinoma of the Pancreas: Case Report, Next-Generation Tumor Profiling, and Literature Review

Chang, J. M., Katariya, N. N., Lam-Himlin, D. M., Haakinson, D. J., Ramanathan, R. K., Halfdanarson, T. R., Borad, M. J., Pannala, R., Faigel, D. O., Moss, A. A. & Mathur, A., Oct 18 2016, (Accepted/In press) In : Case Reports in Gastroenterology. p. 605-612 8 p.

Research output: Contribution to journal › Article

Pancreas

Carcinoma

Acinar Cell Carcinoma

Neoplasms

Neuroendocrine Cells

111 Citations (Scopus)

Metastatic pancreatic cancer: American Society of Clinical Oncology clinical practice guideline

Sohal, D. P. S., Mangu, P. B., Khorana, A. A., Shah, M. A., Philip, P. A., O'Reilly, E. M., Uronis, H. E., Ramanathan, R. K., Crane, C. H., Engebretson, A., Ruggiero, J. T., Copur, M. S., Lau, M., Urba, S. & Laheru, D., Aug 10 2016, In : Journal of Clinical Oncology. 34, 23, p. 2784-2796 13 p.

Research output: Contribution to journal › Review article

gemcitabine

irinotecan

Pancreatic Neoplasms

Practice Guidelines

Comorbidity

74 Citations (Scopus)

Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors

Von Hoff, D. D., Mita, M. M., Ramanathan, R. K., Weiss, G. J., Mita, A. C., Lorusso, P. M., Burris, H. A., Hart, L. L., Low, S. C., Parsons, D. M., Zale, S. E., Summa, J. M., Youssoufian, H. & Sachdev, J. C., Jul 1 2016, In : Clinical Cancer Research. 22, 13, p. 3157-3163 7 p.

Research output: Contribution to journal › Article

docetaxel

Nanoparticles

Appointments and Schedules

Pharmacokinetics

Neoplasms

Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline

Ramanathan, R. K., Korn, R. L., Chiorean, E. G., Liu, H. & Von Hoff, D. D., Aug 1 2016, In : Annals of Oncology. 27, 8, p. 1647-1648 2 p.

Research output: Contribution to journal › Letter

Pancreatic Neoplasms

Positron-Emission Tomography

18 Citations (Scopus)

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas

Ramanathan, R. K., Goldstein, D., Korn, R. L., Arena, F., Moore, M., Siena, S., Teixeira, L., Tabernero, J., Van Laethem, J. L., Liu, H., McGovern, D., Lu, B. & Von Hoff, D. D., Apr 1 2016, In : Annals of Oncology. 27, 4, p. 648-653 6 p., mdw020.

Research output: Contribution to journal › Article

gemcitabine

Positron-Emission Tomography

Pancreas

Adenocarcinoma

Electrons

23 Citations (Scopus)

Safety, pharmacokinetics, and pharmacodynamics of a humanized anti-semaphorin 4D antibody, in a first-in-human study of patients with advanced solid tumors

Patnaik, A., Weiss, G. J., Leonard, J. E., Rasco, D., Sachdev, J. C., Fisher, T. L., Winter, L. A., Reilly, C., Parker, R. B., Mutz, D., Blaydorn, L., Tolcher, A. W., Zauderer, M. & Ramanathan, R. K., Feb 15 2016, In : Clinical Cancer Research. 22, 4, p. 827-836 10 p.

Research output: Contribution to journal › Article

Pharmacokinetics

Safety

Antibodies

Neoplasms

Cell Membrane

22 Citations (Scopus)

Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: A first-in-human, open-label, dose-escalation phase i study with expansion cohort

Burris, H. A., Bakewell, S., Bendell, J. C., Infante, J., Jones, S. F., Spigel, D. R., Weiss, G. J., Ramanathan, R. K., Ogden, A. & Von Hoff, D., Dec 1 2016, In : ESMO Open. 1, 6, e000154.

Research output: Contribution to journal › Article

Ruthenium Compounds

Safety

Maximum Tolerated Dose

Neoplasms

Pharmacokinetics

2015

5 Citations (Scopus)

⁹⁰Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies

Picozzi, V. J., Ramanathan, R. K., Lowery, M. A., Ocean, A. J., Mitchel, E. P., O'neil, B. H., Guarino, M. J., Conkling, P. R., Cohen, S. J., Bahary, N., Frank, R. C., Dragovich, T., Bridges, B. B., Braiteh, F. S., Starodub, A. N., Lee, F. C., Gribbin, T. E., Richards, D. A., Lee, M., Korn, R. L. & 11 others, Pandit-Taskar, N., Goldsmith, S. J., Intenzo, C. M., Sheikh, A., Manzone, T. C., Horne, H., Sharkey, R. M., Wegener, W. A., O'reilly, E. M., Goldenberg, D. M. & Von Hoff, D. D., Jun 7 2015, In : European Journal of Cancer. 51, 14, p. 1857-1864 8 p., 9522.

Research output: Contribution to journal › Article

gemcitabine

Pancreatic Neoplasms

Adenocarcinoma

Therapeutics

Radioimmunotherapy

3 Citations (Scopus)

A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258)

Infante, J. R., Ramanathan, R. K., George, D., Tan, E., Quinlan, M., Liu, A., Scott, J. W. & Sharma, S., 2015, In : Cancer Chemotherapy and Pharmacology. 75, 4, p. 729-737 9 p.

Research output: Contribution to journal › Article

Biological Availability

Tablets

Capsules

Meals

Fats

55 Citations (Scopus)

Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer

Barrett, M., Anderson, K. S., Lenkiewicz, E., Andreozzi, M., Cunliffe, H. E., Klassen, C. L., Dueck, A., McCullough, A. E., Reddy, S. K., Ramanathan, R. K., Northfelt, D. W. & Pockaj, B. A., 2015, In : Oncotarget. 6, 28, p. 26483-26493 11 p.

Research output: Contribution to journal › Article

Triple Negative Breast Neoplasms

Comparative Genomic Hybridization

Glioblastoma

Oligonucleotide Array Sequence Analysis

Disease-Free Survival

13 Citations (Scopus)

Late-stage cancer patients remain highly responsive to immune activation by the selective TLR8 agonist motolimod (VTX-2337)

Dietsch, G. N., Randall, T. D., Gottardo, R., Northfelt, D. W., Ramanathan, R. K., Cohen, P. A., Manjarrez, K. L., Newkirk, M., Bryan, J. K. & Hershberg, R. M., Dec 15 2015, In : Clinical Cancer Research. 21, 24, p. 5445-5452 8 p.

Research output: Contribution to journal › Article

Toll-Like Receptor 8

Neoplasms

Healthy Volunteers

Pharmacokinetics

Biomarkers

2 Citations (Scopus)

Metastatic fibrolamellar hepatocellular carcinoma to the pancreas

Villa, N. A., Pannala, R., Faigel, D. O., Haakinson, D. J., Katariya, N., Ramanathan, R. K., Jaroszewski, D., Lidner, T. K. & Byrne, T., May 1 2015, In : Case Reports in Gastroenterology. 9, p. 266-271 6 p.

Research output: Contribution to journal › Article

Pancreas

Recurrence

Hepatocellular Carcinoma

Liver

Peritoneum